openPR Logo
Press release

New Technologies for HPAPI Manufacturing and Containment

08-29-2019 10:30 AM CET | Media & Telecommunications

Press release from: SMi Group Ltd

New Technologies for HPAPI Manufacturing and Containment

SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production.

At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures.

Key highlights include:

Alternative HPAPI manufacturing technologies to reduce powder exposure and improving safety along with enabling continuous manufacturing
- Alternative drug manufacture through nanocrystal formulations, thin films and hot-melt extrusion/injection moulding that reduces HPAPI powder exposure and improve safety
- Detailing step-by-step process along with the equipment needed to achieve these alternative HPAPI manufacturing techniques
- The advantages of continuous manufacturing utilizing alternative manufacturing technologies

Respiratory HPAPIs: development, formulation and delivery
- Advantages and targets of a respiratory HPAPI
- Equipment and analytical instruments that are most suitable for respiratory containment and safe handling
- Strategies for the development and industrialization process to ensure respiratory HPAPI success
- The current trends in respiratory HPAPIs

Training and managing workers with HPAPI exposure, along with the best available techniques for cleaning and waste management
- Staff training - understanding the equipment they are using
- Due diligence for management to continually assess the HPAPI workspace and keeping operators up to date
- Understand the need to establish expectations surrounding the safe handling of HPAPI

Sponsored by BSP Pharmaceuticals | LONZA | Minakem | SafeBridge Consultants

Highly Potent Active Pharmaceutical Ingredients USA
Conference: October 21st – 22nd
Workshops: October 23rd
Venue: Sheraton Boston Hotel, USA

For delegate enquiries, please contact Fateja Begum on +44 (0)20 7827 6184.

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168

1 Westminster Bridge Road

Event organisers

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Technologies for HPAPI Manufacturing and Containment here

News-ID: 1827795 • Views: 312

More Releases from SMi Group Ltd

Regional CIS Experts to Present at Mobile Deployable Communications 2020
SMi Group Reports: Regional speakers will gather at the 13th Mobile Deployable Communications Conference in Warsaw, Poland on the 30th and 31st January 2020. The 13th annual Mobile Deployable Communications Conference will feature high class presentations by esteemed regional presenters from Poland, Romania, Lithuania and NATO. Register by Monday 30th September to save £400 with the early bird discount. Registrations can be made at: http://www.mobiledeployable.com/pr2 This annual military
An exclusive Aerie Pharmaceuticals speaker interview released for SMi’s Ophtha …
SMi Group Reports: Vice President of Aerie Pharmaceuticals to present at SMi’s Ophthalmic Drugs conference commencing on 18th- 20th November 2019 in London SMi catches up with Aerie Pharmaceuticals Vice President, Chemistry, Mitchell de Long as a speaker for the Ophthalmic Drugs conference taking place on the 18th- 20th November 2019 in London. As Europe’s leading Ophthalmic Drugs conference, the three-day agenda will explore new discoveries in the treatment of ocular
Exclusive Sanofi R&D speaker interview released for 5th Lyophilization USA Confe …
SMi Group reports: Principal Scientist from Sanofi R&D is set to present at SMi’s 5th Annual Lyophilization 2 Day Conference taking place in Boston on October 23 – 24, 2019. This year’s conference will explore novel and developing technologies that tackle current challenges and push innovation in the world of lyophilization. Bringing together industry leaders, it is a platform to discuss relevant topics that delve into alternative lyophilization approaches, applied statistical
Financial Mechanisms to Ensure Successful Energy from Waste Projects
SMi Reports: With recent news that the Alfanar Group will be investing £1 billion in a number of waste to energy projects in the UK, it comes at a time with the UK government's commitment to “net zero” greenhouse gas (GHG) emissions by 2050. The forecast is that the undisclosed projects will utilise over a million tonnes of waste which would have gone to landfill*. This further bolsters the energy

All 5 Releases


More Releases for HPAPI

Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Researc …
This report studies the global High Performance Active Pharmaceutical Ingredients (HPAPI) market status and forecast, categorizes the global High Performance Active Pharmaceutical Ingredients (HPAPI) market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Bristol-Myers Squibb Novartis Sanofi Aventis Pfizer Lonza Novasep Hospira
HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca
Peter Marshall from AstraZeneca will be speaking at SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference which will take place in London on 13th-14th May. He will be discussing the latest developments in the industry with a specific focus on the principles of pharmaceutical containment in isolator design. Ahead of the conference, SMi had interviewed him where he gave a taster of what he will be discussing. Peter said: “The
The Latest Techniques in HPAPI Facility Design
Amongst the myriad of potential pitfalls for the Highly Potential Active Pharmaceutical Ingredients (HPAPI) industry there is a requirement for all parties involved to have a blueprint in place to ensure all containment procedures are followed correctly. Yet, there is also a need to ensure that operations are maintained at the highest standards. At SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients Conference these issues will be discussed along with
HPAPI (High Potency Active Pharmaceutical Ingredients) Market Report 2018: Segme …
Global HPAPI (High Potency Active Pharmaceutical Ingredients) market research report provides company profile for Lonza, Novasep, Thermofisher Scientific, Alkermes, Cambrex, Dishman, Dr. Reddy’S and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report
SMi’s HPAPI 2018 Conference: Exclusive Interview Released with HPAPI Project S …
SMi are delighted to have our Chairman, Speaker and Workshop Host, Justin Mason-Home, Director, HPAPI Project Services Limited, onto the speaker panel for HPAPI 2018! About Justin: Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the pharmaceutical, biochemical, chemical and other industries. He has held senior positions and worked globally in potent biopharmaceutical occupational health and safety
Exclusive Interview Released with HPAPI Project Services
SMi are delighted to have our Chairman, Speaker and Workshop Host, Justin Mason-Home, Director, HPAPI Project Services Limited, onto the speaker panel for HPAPI 2018! About Justin: Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the pharmaceutical, biochemical, chemical and other industries. He has held senior positions and worked globally in potent biopharmaceutical occupational health and safety